Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 8Neoplasm Metastasis 6Breast Neoplasms 6Thyroid Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Pleural Effusion 2Ovarian Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Relapsed Pediatric Solid Tumor 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Non-small Cell Lung Cancer Metastatic 1

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × vandetanib × Clear all
NCT00686036 2016-12-21

ZENITH

Sanofi

Phase 2 Terminated
17 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

NCT00659438 2016-12-05

Efficacy and Safety of Zactimaâ„¢ in Patients With Castration-refractory Metastatic Prostate Cancer

Sanofi

Phase 2 Completed
95 enrolled 12 charts
Genitourinary

Prostatic Neoplasms

NCT00498797 2016-10-07

E3-Hormone Refractory Prostrate Cancer Taxotere Combination

Sanofi

Phase 2 Completed
86 enrolled 8 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00757692 2013-02-20

Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer.

British Columbia Cancer Agency

Phase 2 Completed
74 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡